Inogen | INGN - Cash And Equivalent


Inogen reported $106.48M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Accuray USD 41.29M 22.05M Dec/2025
AngioDynamics USD 41.64M 14.26M Sep/2025
Artivion USD 55.76M 9.14M Mar/2026
AtriCure USD 146.16M 21.26M Mar/2026
Baxter International USD 2.02B 51M Mar/2026
Becton, Dickinson and Co. USD 813M 73M Mar/2026
Boston Scientific USD 1.45B 512M Mar/2026
Chart Industries USD 267.9M 98.1M Mar/2026
Cooper Companies USD 124.9M 14.3M Dec/2025
Dexcom USD 1.12B 200.5M Mar/2026
Edwards Lifesciences USD 2.4B 538M Mar/2026
Globus Medical USD 560.95M 34.79M Mar/2026
Inogen USD 106.48M 2.79M Sep/2025
Insulet USD 480.4M 235.7M Mar/2026
Medtronic USD 1.15B 135M Dec/2025
Orthofix International USD 120.28M 38.25M Mar/2026
Philips EUR 2.79B 882M Dec/2025
ResMed USD 1.66B 243.44M Mar/2026
Steris USD 423.7M 104.5M Dec/2025
Stryker USD 2.88B 1.13B Mar/2026
Tandem Diabetes Care USD 179.32M 88.69M Mar/2026
Teleflex USD 309.41M 69.15M Mar/2026
X T L Biopharmaceuticals USD 371K 449K Dec/2024
Zimmer Biomet Holdings USD 424.2M 167.7M Mar/2026